Clinical trials
Chronic Hepatitis clinical trials
Below are recruiting chronic hepatitis clinical trials, each written for real people, not researchers. We’re tracking 131 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07449091Recruiting
HBV undetectable equals untransmissible study
This study checks if having undetectable hepatitis B virus (HBV) means you cannot pass it to others. It tests this idea in people with chronic HBV who are on treatment, those not on treatment, and healthy controls.
New York, New YorkAges 18–65 - NCT06874127Recruiting
Predicting liver repair in hepatitis B after treatment
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
BeijingAges 18 years+ - NCT07275918RecruitingPhase 1
Study of SA1211 injection for chronic hepatitis B
This study tests a new injection called SA1211 for people with chronic hepatitis B. It will help see if the treatment is safe and how it works in the body.
Changchun, JilinAges 18–65 - NCT03792919RecruitingPhase 4
Stopping long-term hepatitis B medicine vs continuing
This study compares outcomes for people with chronic hepatitis B who have long-term, stable viral suppression: stopping their antiviral medicine versus continuing it. It may help answer whether it’s safe to stop treatment in the right patients.
Hong Kong, Hong Kong SARAges Any age - NCT07257562Recruiting
Testing gut bacteria and amino acids to clear hepatitis B surface marker
This study tests whether a combination of a harmless gut bacterium (Bacteroides fragilis) and branched-chain amino acids (BCAAs, which are building blocks of protein) can help your body clear the hepatitis B surface antigen (HBsAg) from your blood. This may mean moving closer to a functional cure for chronic hepatitis B.
Fuzhou, FujianAges 18 years+ - NCT06906016Recruiting
New blood tests for hepatitis B
This study looks at new blood tests (biomarkers) to better understand chronic hepatitis B and how it affects treatment decisions. It may help doctors find better ways to manage your condition.
Créteil, CréteilAges 18 years+ - NCT06853886Recruiting
Genetic study for hepatitis B patients to find new treatment pathways
This study looks at the genes of people with chronic hepatitis B (HBV) to find why some people's immune cells (B cells and NK cells) stop working properly. The goal is to discover new ways to treat the disease.
LimogesAges 18 years+ - NCT06777173Enrolling by invitation
Antiviral and Immunotherapy for Chronic Hepatitis B
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
BeijingAges 18–65 - NCT05853718RecruitingPhase 4
Tenofovir treatment for hepatitis B during pregnancy
This study tests tenofovir alafenamide (TAF) to lower hepatitis B in pregnant people and reduce the chance of passing it to the baby. You may be able to join if you’re pregnant with active hepatitis B and meet safety lab and pregnancy ultrasound requirements.
Hangzhou, ZhejiangAges 20–40 - NCT06364930RecruitingPhase 4
SGLT2 inhibitor to prevent liver problems in hepatitis B and diabetes
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
Hong KongAges 18 years+ - NCT05597488Recruiting
Measuring pressure to predict varice treatment response
This study checks whether a special ultrasound-guided measurement of blood pressure in your liver can help predict how well endoscopic treatment (banding varices or injecting bleeding sites) will work. It aims to improve outcomes by identifying who is more likely to respond.
Hong Kong, Hong KongAges 18–75 - NCT05466071Recruiting
TAF to prevent hepatitis B transmission during pregnancy
This study tests whether a daily antiviral pill called TAF can reduce the risk of passing hepatitis B to your baby. It is for pregnant women with high levels of the virus who are between 24 and 28 weeks along.
Guangzhou, GuangdongAges 20–40 - NCT03773887Recruiting
Study of liver inflammation and healing in alcohol-related liver disease
This study compares patterns of liver inflammation and the liver’s healing ability in people with alcohol-related liver disease, using blood tests and (in most cases) a liver tissue sample. It may help doctors better understand what is happening in the liver and how it may recover.
LilleAges 18–70 - NCT07270809Recruiting
Chronic liver disease with organ failure: early outcomes study
This study follows patients with chronic liver disease who are hospitalized non-electively for organ failure, to understand the course of illness and outcomes over six months. It may help doctors improve care for similar patients.
New Delhi, National Capital Territory of DelhiAges 18–70 - NCT05937178Recruiting
Real-World Study to Optimize Hepatitis B Tablet Treatment
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
Hefei, AnhuiAges 18–80 - NCT05686785Recruiting
Test how reliable a liver scan is in chronic hepatitis
This study checks whether a “liver stiffness” scan (called transient elastography) gives consistent, dependable results in adults with long-term viral hepatitis. It may help improve how doctors monitor liver changes over time.
Helsingborg, Skåne CountyAges 18 years+ - NCT06550622Recruiting
Better Detection of Hepatitis B Virus After Treatment
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT05905172RecruitingPhase 3
Hydronidone for long-term treatment of hepatitis B scarring
This Phase 3 study tests whether hydronidone capsules can help people with long-term hepatitis B–related liver scarring (fibrosis). It aims to track whether treatment reduces or delays serious liver complications over time.
Beijing, Beijing MunicipalityAges 18–65 - NCT06923280Recruiting
Sequential Pegylated Interferon After RNA-Targeted Hepatitis B Therapy
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
Beijing, ChinaAges 18–80 - NCT01644903Recruiting
Checking biomarkers after a liver transplant
This study follows people who are getting a liver transplant (including repeat transplants) to monitor changes in their body using test results. It may help doctors understand how patients are doing after transplant and improve care over time.
Chicago, IllinoisAges 18 years+ - NCT07095192Recruiting
Hepatitis C testing and treatment study in Canada
This study looks at how to make hepatitis C testing and treatment easier to access in Canada. It involves different people, like those at risk, healthcare workers, and policy makers, to find better ways to offer care.
Montreal, QuebecAges 18 years+ - NCT06953921Recruiting
Liver disease and confusion: does albumin level matter?
This study looks at whether low albumin levels in the blood are linked to more severe confusion caused by liver disease. It may help doctors understand how to better manage hepatic encephalopathy.
SohagAges 18 years+ - NCT05392387Recruiting
Treatment and outcomes study for long-term hepatitis B
This trial looks at people with long-term hepatitis B infection and studies how treatment may affect health over time. It may help you understand whether your care improves outcomes for chronic hepatitis B.
Changsha, HunanAges 18–79 - NCT04588077RecruitingPhase 4
Two-dose vs three-dose hepatitis B vaccine for cirrhosis
This study compares giving the hepatitis B vaccine in 2 doses versus 3 doses for people with cirrhosis who do not yet have protection against hepatitis B. It may help your care team choose the schedule most likely to build lasting immunity.
Baltimore, MarylandAges 18 years+
Hear when a new Chronic Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic hepatitis?
- Yes. Clin2 currently lists 131 recruiting chronic hepatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic hepatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic hepatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.